{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.0","upperLimit":"18.7","value":"5.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"}],"units":"Participants"}],"description":"PFS is the time from the date of first dosing until the date of objective disease progression or death (by any cause) regardless of whether the participant discontinues the study treatments. Progression is identified based on CT scans evaluated by IRC per Lugano criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group D: Open label AZD4205 at the RP2D, once daily (Phase 2)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG000","title":"AZD4205 Group D"}],"paramType":"MEDIAN","populationDescription":"Evaluable for Survival Set (all dosed and central pathology confirmed PTCL patients)","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Part B: Progression Free Survival (PFS) Assessed by IRC","type":"SECONDARY","unitOfMeasure":"months"}